TrialInvestigational new drugs2014

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.

Yoon-Koo Kang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.